Login

Subscribe   My Account  

Login
Username:
Password:
Remember Me
Login securely
 
Breaking News for Income Investors

The U.S. Dollar is Plummeting
Learn how to profit from the decline of the U.S. dollar...

Capture Dividend Yields of up to 23.1%
Get the full details on how you can capture dividend yields of up to 23.1%.

Where T-Bills Pay 14.2%
It's now easy to capture double-digit yields all over the world.

Foreign Stocks are Skyrocketing
Last year, Chinese stocks soared +180%. Brazil jumped +72%. And investors in the Ukraine...


Sharp +50% Gains at Biogen (BIIB)

Published: February 18, 2008

As shareholders, we all like to see our company launch an exciting new product. Maybe it's a potential blockbuster drug, a trendy cell phone, or a popular new software title. Regardless of the product, the introduction of a big hit can often bring in billions in incremental revenues and send a company's shares soaring.

However, before those products can hit the market, they must first graduate from the research and development (R&D) department. Investments made in R&D may represent cash going out the door today, but they can pay off big tomorrow -- and often make the difference between a stagnant company and one with heady growth on the horizon.

With all this in mind, Paul Tracy, editor of our StreetAuthority Market Advisor newsletter, is always on the lookout for innovative companies that make the most of their R&D budgets. And in the August 2005 newsletter, he set out specifically to identify a select group of firms that go above and beyond when it comes to new product development.

That search turned up a number of winning stocks for readers, including biotech giant Biogen Idec (Nasdaq: BIIB, $62.20). As Paul pointed out at the time, Biogen maintains the third-largest R&D budget in its industry -- pumping more than 30% of its $2-plus billion in annual revenues into R&D. As a result, the company had a full pipeline of promising new drugs in various stages of clinical trials, including treatments for everything from psoriasis to cancer to congestive heart failure.

Since that initial profile, Biogen's earnings have more than tripled, soaring from $160 million in 2005 to $545 million over the past year. Meanwhile, Wall Street has recognized the company's success, pushing the shares from $41.58 to Friday's close of $62.20 -- a sharp gain of nearly +50%.

In this month's Market Advisor newsletter, Paul zooms in on another company that often turns new products into an influx of cash. The firm operates a chain of casual dining restaurants whose innovative menu and relaxed atmosphere have given it the highest customer loyalty scores in the industry. And the brand is just hitting its stride, with a store base that could eventually quadruple from the current 1,100 units to more than 4,000. Those along for the ride could see the shares follow a similar path. Follow this link to learn more.
 



Nathan Slaughter
StreetAuthority Staff Writer




Income Security of the Month
Our "Income Security of the Month" for July 2008 invests in a fast-growing overseas market that doesn't get much exposure in the mainstream financial press. And although it typically makes enormous annual dividend payments -- it has paid an average dividend of 24.9% per year over the past five years -- this fund is perhaps most appealing for its total return potential. Specifically, the fund has delivered total returns of +263.9% since 2003, and it ranks in the top 10% of its category over the past decade.

 

Top 10 Stocks for 2008!
Since we began publishing this report back in 2003, the picks we've featured have consistently beaten the broader market -- delivering average gains of +21.3% per year and outperforming the S&P by a nearly 2-to-1 margin. Act now to reserve your copy of our newest report -- Top Ten Stocks for 2008.

 



Success Trading -- 365 Days Without a Loss
Success Trading Group scored 52 wins in 52 weeks! Get their weekend newsletters free. 

High-Yield Investing
If you're looking for both high yields and enormous capital gains, then you need to learn more about our "Income Stock of the Month."

 

Stephen Leeb's Market Forecast
Receive a free ongoing, PhD level Wall Street education in how the markets work so that you can see into the future and position yourself accordingly.

Investor's Business Daily (IBD)
Get 10 Free Issues of Investor's Business Daily (IBD) – Plus 2 Free Weeks of Investors.com

 

High-Yield Investing


High-Yield International


The ETF Authority


Market Advisor


Half-Priced Stocks


Global Dividend Opportunities


Investor Update



 


Google
 
Web StreetAuthority.com


About StreetAuthority    Email Newsletters    My Subscriptions    Manage My Account    Job Opportunities
Contact Us    Affiliates    Disclaimer    Help    Site Map

© Copyright 2001-2008 StreetAuthority, LLC  All Rights Reserved